Professor Giovanna Mallucci
MRC Toxicology Unit
PO Box 138
University of Leicester
Lancaster Road, Leicester
LE1 9HN, UK
Tel: +44 (0)116 252 5550 (/5597 lab)
Qualifications and Personal History
Professor, Department of Cell Physiology and Pharmacology, University of Leicester 2008 – present
Programme Leader, MRC Toxicology Unit 2008 – present
SciAm 50 Award: ‘Progress against Prions’; for leadership in research, 2007
Consultant Neurologist, National Hospital for Neurology and Neurosurgery 2005 – 2012
Group Leader, MRC Prion Unit 2001-2008
PhD (London) Neurogenetics, 2000
Training in Internal Medicine and Neurology, 1989-95
MBBS (MD) (London), 1988
BA (Oxon) Physiological Sciences, 1985
Enhancing nucleotide metabolism protects against mitochondrial dysfunction and neurodegeneration in a PINK1 model of Parkinson’s disease. Roberta Tufi, Sonia Gandhi, Inês P. de Castro, Susann Lehmann, Plamena R. Angelova, David Dinsdale, Emma Deas, Hélène Plun-Favreau, Pierluigi Nicotera, Andrey Y. Abramov, Anne E. Willis, Giovanna R. Mallucci, Samantha H. Y. Loh & L. Miguel Martins. Nature Cell Biology 2014 16,157–166
Enhancing nucleotide metabolism protects against mitochondrial dysfunction and neurodegeneration in a PINK1 model of Parkinson’s disease
Oral Treatment Targeting the Unfolded Protein Response Prevents Neurodegeneration and Clinical Disease in Prion-Infected Mice. Julie A. Moreno, Mark Halliday, Colin Molloy, Helois Radford, Nicholas Verity, Jeffrey M. Axten, Catharine A. Ortori, Anne E. Willis, Peter M. Fischer, David A. Barrett and Giovanna R. Mallucci, Sci Transl Med 2013 Vol. 5, Issue 206, p. 206ra138
Oral Treatment Targeting the Unfolded Protein Response Prevents Neurodegeneration and Clinical Disease in Prion-Infected Mice
Sustained translational repression by eIF2α-P mediates prion neurodegeneration. Julie A. Moreno, Helois Radford, Diego Peretti, Joern R. Steinert, Nicholas Verity, Maria Guerra Martin, Mark Halliday, Jason Morgan, David Dinsdale, Catherine A. Otori, David A. Barrett, Pavel Tsaytler, Anne Bertolotti, Anne E. Willis, Martin Bushell & Giovanna R. Mallucci. Nature 2012 May 6;485(7399):507-11.
Sustained translational repression by eIF2α-P mediates prion neurodegeneration
Single localized treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease. White M, Farmer M, Mirabile I, Brandner S, Collinge J and Mallucci G. PNAS 2008, 32 10238-43.
RNAi against PrP prolongs survival and is neuroprotective in prion disease
Preview in same issue: ‘Reversal of misfolding: prion disease behavioral and physiological impairments recover following postnatal neuronal deletion of the PrP gene’ Federoff H.J. and Mhyre T.R. Neuron 2007 53, 315-7.
Preview: reversal of neuronal dysfunction
Targeting cellular prion protein reverses early cognitive deficits and neurophysiological dysfunction in prion-infected mice. Mallucci GR, Dickinson A, White M, Husna Khatun, Andrew D. Powell, Sebastian Brandner, John G. R. Jefferys and Collinge J. Neuron 2007 53, 323-335.
Reversal of early neuronal dysfunction in prion disease
Depleting neuronal PrP during prion infection prevents disease and reverses spongiosis. Mallucci G, Dickinson A, Linehan J, Brandner S, Kloehn P and Collinge J. Science 2003 302, 871-4.
Targeting PrP in prion infection prevents disease
Post-natal PrP knockout alters hippocampal CA1 properties but does not result in neurodegeneration Mallucci GR, Asante E, Ratte S, Linehan J, Gowland I, Jefferys J and Collinge J. EMBO J 2002 21, 202-10.
Adult onset knockout model of PrP
The Role of GPI-anchored PrPC in Mediating the Neurotoxic Effect of Scrapie Prions in Neurons. Helois E. Radford and Giovanna R. Mallucci
The Role of GPI-anchored PrP(C) in Mediating the Neurotoxic Effect of Scrapie Prions in Neurons.
White MD, Mallucci GR. RNAi for the Treatment of Prion Disease: A Window for Intervention in Neurodegeneration? CNS Neurol Disord Drug Targets. 2009 Nov 1. [Epub ahead of print] PubMed PMID: 19702576.
White MD, Mallucci GR. Therapy for prion diseases: Insights from the use of RNA interference. Prion. 2009 Jul 16;3(3). [Epub ahead of print] PubMed PMID: 19597349.http://www.nature.com/emboj/journal/v21/n3/pdf/7594241a.pdf
Therapy for prion diseases: Insights from the use of RNA interference
Rational targeting for prion therapeutics. Mallucci G and Collinge J. Nature Reviews Neuroscience 2005 6, 23-34.
Rational targeting for prion therapeutics